A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.